Future Directions in Research and Treatment
Looking to the future of multiple sclerosis care, the panel of thought leaders pose important questions that remain to be answered in the research and treatment of multiple sclerosis.
Understanding Varying Latency Periods for Epstein-Barr Virus and Onset of MS
Alberto Ascherio, MD, DrPH, addresses the range of latency periods for Epstein-Barr virus and the impact on onset multiple sclerosis.
Translating New Advances to the Clinic
Alberto Ascherio, MD, DrPH; Anne Cross, MD; and Michael Racke, MD, discuss implications for patient communication and other advances from bench to bedside.
Therapeutic Implications Regarding the Role of Epstein-Barr Virus in MS
The expert panelists comment on intervention efforts underway to address multiple sclerosis prevention and treatment.
Elucidating the Association Between Epstein-Barr Virus and Multiple Sclerosis
Alberto Ascherio, MD, DrPH, recaps key findings and learning from a recently published study that he coauthored demonstrating a causal relationship between MS and Epstein-Barr virus.
Validating and Expanding the Use of RetiSpec: Sharon Cohen, MD, FRCPC
March 18th 2022The neurologist and assistant professor at the University of Toronto commented on the next research efforts needed to further validate and demonstrate the diagnostic capabilities of RetiSpec. [WATCH TIME: 3 minutes]
MDA 2022 Highlights the Therapeutic Advances for Neuromuscular Diseases: Donald S. Wood, PhD
March 17th 2022The president and CEO of the Muscular Dystrophy Association spoke about the highlights of this year’s annual meeting and the recent therapeutic advances for neuromuscular disorders. [WATCH TIME: 3 minutes]
Managing New Therapies for Neuromuscular Diseases: Jinsy Andrews, MD, MSc
March 16th 2022The director of neuromuscular clinical trials at Columbia University Irving Medical Center shared her perspective on the challenges of familiarizing oneself with the influx of novel medications for neuromuscular diseases. [WATCH TIME: 3 minutes]
The Revolution in Limb-Girdle Muscular Dystrophy With Gene Therapies: Nicholas E. Johnson, MD, MSci
March 16th 2022The division chief of neuromuscular disorders and vice-chair of research at Virginia Commonwealth University offered his insight into the advances in genetic approaches to LGMD. [WATCH TIME: 2 minutes]
Diagnostic Delays and the Importance of the Physician-Patient Relationship: Amy Shinneman
March 15th 2022The 2022 MDA National Ambassador and patient with Bethlem myopathy spoke to the critical need to improve diagnosis delays in neuromuscular disorders and effective communication between patients and their physicians. [WATCH TIME: 2 minutes]
Assessing, Validating Clinically Relevant Biomarkers for Alzheimer Disease: Jefferson Kinney, PhD
March 15th 2022The founding chair of the department of brain health at the University of Nevada Las Vegas discussed the plethora of Alzheimer disease biomarkers and the need for consensus on the value of each. [WATCH TIME: 3 minutes]
Where Tolebrutinib and Other BTK Inhibitors Fit in the MS Treatment Landscape: Jiwon Oh, MD, PhD
March 15th 2022The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital discussed how investigational BTK inhibitors will be used among an ever-growing MS treatment toolbox. [WATCH TIME: 3 minutes]
The Need to Elevate Patient Voices in Neuromuscular Disorders: Amy Shinneman
March 14th 2022The 2022 MDA National Ambassador and patient with Bethlem myopathy spoke to the importance of including the patient perspective at medical meetings to improve the care paradigm in neuromuscular disorders. [WATCH TIME: 3 minutes]
The Future of Retinal Imaging to Predict Alzheimer Disease: Sharon Cohen, MD, FRCPC
March 14th 2022The neurologist and assistant professor at the University of Toronto provided insight on the clinical use of retinal imaging tools like RetiSpec and the need for further validation of these approaches in Alzheimer disease. [WATCH TIME: 2 minutes]
Building Research on Neurodegeneration and Developing Future Researchers: Jefferson Kinney, PhD
March 11th 2022The founding chair of the department of brain health at the University of Nevada Las Vegas provided background on how a newly funded NIH grant will contribute to translational neuroscience research infrastructure. [WATCH TIME: 3 minutes]
Overview of Tolebrutinib’s Positive 18-Month Data in Relapsing MS: Jiwon Oh, MD, PhD
March 10th 2022The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital provided insight on the tolebrutinib’s mechanism of action, and new data presented at ACTRIMS Forum 2022. [WATCH TIME: 4 minutes]
Characteristics of and Prevention Methods for Cerebral Palsy: Bhooma Aravamuthan, MD, DPhil
March 9th 2022The assistant professor of pediatric neurology at Washington University in St. Louis provided an overview of cerebral palsy and ways to reduce the risk of developing the condition. [WATCH TIME: 3 minutes]